Vaccine. 2010 Jul 19;28(32):5153-60.

Human myeloid dendritic cells for cancer therapy: does maturation matter?

Source

University Cell Immunotherapy Center, Babak Research Institute, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic. katka.skalova@gmail.com

Abstract

Dendritic cells form the connection between innate and adoptive mechanisms of the immune system. As antigen-presenting cells, dendritic cells are capable of presenting tumour antigen and effectively stimulating immune response targeted against a tumour. A number of preclinical and clinical studies document dendritic cells' potential in anti-cancer treatment. Increasing knowledge of dendritic cell biology is leading to improved methods for their preparation for clinical application. Unfortunately, there is to date no consensus specifying optimal conditions for dendritic cell preparation in vitro. This review summarizes the methods used for preparing myeloid dendritic cells derived from monocytic precursors while focusing on cytokine cocktails used for their growth, maturation, and functional adjustment.

PMID:: 20665974; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Cancer - MedlinePlus Health Information

Supplemental Content

Related citations

Human myeloid dendritic cells for cancer therapy: Does maturation matter? [Vaccine. 2010]
Human myeloid dendritic cells for cancer therapy: Does maturation matter?
Skalova K, Mollova K, Michalek J. Vaccine. 2010 May 28; . Epub 2010 May 28.
Review Dendritic cells: still a promising tool for cancer immunotherapy. [Clin Transl Oncol. 2007]
Review Dendritic cells: still a promising tool for cancer immunotherapy.
Aragoneses-Fenoll L, Corbí AL. Clin Transl Oncol. 2007 Feb; 9(2):77-82.
Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients. [Exp Hematol. 2000]
Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients.
Ratta M, Curti A, Fogli M, Pantucci M, Viscomi G, Tazzari P, Fagnoni F, Vescovini R, Sansoni P, Tura S, et al. Exp Hematol. 2000 Aug; 28(8):931-40.
Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. [Blood. 2003]
Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen.
Gilliet M, Kleinhans M, Lantelme E, Schadendorf D, Burg G, Nestle FO. Blood. 2003 Jul 1; 102(1):36-42. Epub 2003 Jan 30.
Review Dendritic cell biology and cancer therapy. [Cancer Immunol Immunother. 2004]
Review Dendritic cell biology and cancer therapy.
Whiteside TL, Odoux C. Cancer Immunol Immunother. 2004 Mar; 53(3):240-8. Epub 2003 Dec 18.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Human myeloid dendritic cells for cancer therapy: does maturation matter?
Human myeloid dendritic cells for cancer therapy: does maturation matter?
Vaccine. 2010 Jul 19 ;28(32):5153-60.

PubMed
Common mullein (Verbascum thapsus L.): recent advances in research.
Common mullein (Verbascum thapsus L.): recent advances in research.
Phytother Res. 2005 Sep ;19(9):733-9.

PubMed
Cyclins and CDKS in development and cancer: lessons from genetically modified mi...
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
Front Biosci. 2006 Jan 1 ;11:1164-88.

PubMed
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
Expert Opin Biol Ther. 2009 Aug ;9(8):1087-98.

PubMed
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
Expert Opin Pharmacother. 2009 Dec ;10(17):2913-25.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: